DAFTAR PUSTAKA
1. Peter BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health Syst Pharm. 2000;57(7):645-59
2. Suomela S. Studies on the molecular patogenesis of psoriasis. Helsinki University Biomedical Dissertations. 2004; 52:1-81
3. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types os psoriasis vulgaris. J. Am. Acad. Dermatol. 1985; 13(3): 450-6
4. Gudjonsson J, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2012;18:377
5. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. Expert Rev. Dermatol. 2006;1(1):63-75
6. Pane HN. Profil kadar leptin serum pada berbagai derajat keparahan penderita psoriasis vulgaris di rumah sakit umum pusat haji adam malik medan. Universitas Sumatera Utara. 2013; 40: 1
7. Coimbra S, Oliveira H, Figueiredo A. Psoriasis: epidemiology, clinical and histological features, triggering factors, assessment of severity and psychosocial aspects. Intechopen. 2012; 69-88
8. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510-8
9. Ortonne JP. Recent developments in the understanding of the patogenesis of psoriasis. Br J Dermatol. 1999;54: 1-7
10.Bos JD, De Rie MA. The patogenesis of psoriasis: immunological facts and speculations. Immunol Today. 1999; 20: 40-6
11.Chang EY, Hammerberg C, Fisher G, Baadsgaard O, Ellis CN, Voorhees JJ, et al. T cell activation is potentiated by cytokines released by lesional psoriatik, but not normal, epidermis. Arch Dermatol. 1992; 128: 1479-85 12.Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and
regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatik lesional T lymphocytes stimulate proliferation among psoriatik uninvolved, but not normal, stem keratinocytes. J Clin Invest. 1995; 95: 317-27
13.Saiag P, Coulomb B, Lebreton C, Bell E, Dubertret L. Psoriatik fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science. 1985; 230: 669-72
15.Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis. 2002; 5: 237-56
16.Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis. 2002; 5: 231-6
17.Nickoloff BJ. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J Investig Dermatol Symp Proc. 2000; 5: 67-73
18.Glickman FS. Lepra, psora, psoriasis. J Am Acad Dermatol. 1986; 14(5):863-6
19.Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005; 352: 1899–912 20.Bowcock AM, Krueger JG. Getting under the skin: the immunogenetiks of
psoriasis. Nat Rev Immunol. 2005; 5(9):699-711
21.Darouti ME, Hay RA. Psoriasis: Highlights on patogenesis, adjuvant therapy and treatment of resistant and problematic cases (part I). J Egypt Women Dermatol Soc. 2010; 7: 64 - 70
22.Nograles KE, Brasington RD, Bowcock AM. New insights into the patogenesis and genetiks of psoriatik arthritis. Nat Clin Pract Rheumatol. 2009;5(2):83-91
23.Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007 Nov-Dec;25(6):606-15
24.Diallo M. Psoriasis Epidemiology. J Clinic Case Reports. 2012; 2: 8
25.Lowes MA, Bowcock AM, Krueger JG. Patogenesis and therapy of psoriasis. Nature. 2007; 445: 866-73
26.Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis patogenesis. Int J Exp Pathol. 2009; 90(3): 232–48
27.Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005; 64(2):18–23
28.Long CC, Finlay AY, Averill RW. The rule of hand:4 hand areas =2FTU=1g. Arch Dermatol. 1992;128:1129-30
29.Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol. 1991;124:565-70
30.Carvalho JR, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimune diseases. J Clin Immunol. 2007; 27(3):246-56
31.Puxeddu I, Ribatti D, Crivellato E, Schaffer FL. Mast cells and eosinophils: A novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol. 2005;116:531-6
32.Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001; 15: 16–7
Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol. 2007; 156: 899–905
34.Chang YC, Wu WM, Chen CH, Lee SH, Hong HS, Hsu LA. Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in Taiwan. Br J Dermatol. 2007; 156: 642–5
35.Chen HH, Tseng MP, Tsai TF. An epidemiologic study of Taiwanese psoriatic patients in a single clinic. Dermatolo Sinica. 2003; 21: 216–24 36.Sinniah B , Saraswathy DS, Prashant BS. Epidemiology of psoriasis in
malaysia: a hospital based study. Med J Malaysia. 2010; 65(2):112-4 37.Larsson PA, Liden S. Prevalence of skin diseases among adolescents 12–
16 years of age. Acta Derm Venereol.1980; 60:415–23
38.Augustin M, Glaeske G, Radtke MA et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010; 162:633–6
39.Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004; 9:136–9
40.Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol. 1981; 61:344–6
41.Hellgren L. The Prevalence in Sex, Age and Occupational Groups in Total Populations in Sweden. Morphology, Inheritance and Association with other Skin and Rheumatic Diseases. Psoriasis. 1967; 34(2): 126-9
42.Cooperative Psoriasis Study Group Distribution of psoriasis in China: A nationwide screening in 1984. Chinese Journal of Dermatology. 1986; 19:253–62
43.Adam BA. Psoriasis in a hospital population. Med. J. Malaysia.1980; 34:379-4
44.Stevenson O, Zaki I. Introduction to Psoriasis. Hospital Pharmacist. 2002; 9:187-90
45.Stahle M, Sanchez F. Immunogenetics of psoriasis. ASHI Quarterly. 2006; 19:16-9
46.Farber EM, Nall L. Natural history of psoriasis in 5600 patients. Dermatologica. 1974; 148:1-18
47.Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom. A population based Study. Arch Dermatol.2005; 141:1537-41
49.Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis and Rheumatism. 2009; 61(10):1373-8 50.Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis:
consequences, mechanisms, and interventions. Dermatologic Clinics. 2005; 23(4): 681–94
51.Kundakci N, Ursen UT, Babiker MO, Urgey EG. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. International Journal of Dermatology. 2002; 41(4): 220–4
52.Cimmino MA. Epidemiology of psoriasis and psoriasis arthritis. Reumatismo. 2007;59(1):19-24
53.Olsen AO, Grjibovski A, Magnus P, Tambs K, Harris JR. Psoriasis in Norway as observed in a population based Norwegian twin panel. Br J Dermatol. 2005; 153;346-51
54.Kassi k, Mienwoley OA, Kouyate M, Koui S, Kouassi KA.Severe Skin Forms of Psoriasis in Black Africans: Epidemiological, Clinical, and Histological Aspects Related to 56 Cases. Hindawi Publishing Corporation Autoimmune Diseases. 2013; 56 (4):1032
55.Chang YT, Chen TJ, Liu PC et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009; 89:262–6
56.Medical news today Psoriasis: Fact Sheet. 2006; http://www.medicalnewstoday.com
57.Campalani E, Barker JN. The clinical genetics of psoriasis. Current Genomics. 2005; 6:51-60
58.Barker JN. Genetic aspects of psoriasis. Clin Exp. Dermatol. 2001; 26:321-5
59.Lin TY, et al. Quality of Life in Patients with Psoriasis in Northern Taiwan. Chang Gung Med J. 2011;34:186-96
60.Landegren J, Mobacken H. Psoriasis related conditions. A pictorial atlas. Clinical presentation and differential diagnosis. Skogs Boktryckeri AB Trelleberg.1995; 1-21.
61.Oka A, Mabuchi T, Ozawa A et al. Current understanding of human genetics and genetic analysis of psoriasis. J Dermatol .2012; 39:231–41 62.Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over
the age of 60 years: is elderly-onset psoriasis a distinct subtype? International Journal of Dermatology. 2012; 51: 53–8
63.Felix Boon-Bin Yap. Psoriasis among Sarawakian natives in a tertiary skin centre in Sarawaka. Australasian Journal of Dermatology. 2010; 20: 45-6 64.Papp K , Valenzuela F, Poulin Y, Bernstein G, Wasel N. Epidemiology of
Cutan Med Surg. 2010;14(4):167-74
65.Nofal A, Makhzangy AL, Attwa I, Nassar E, Abdalmoati A. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J. Eur. Acad. Dermatol Venerol. 2009; 23: 803–6
66.Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp. Dermatol. 2010; 35: 645–9
67.Zablotna M, Sobjanek M, Nedoszytko B, Lange M, Kozicka D, Glen J, et al. Association of psoriasis with the VEGF gene polymorphism in the northern Polish population. J. Eur. Acad. Dermatol Venerol. 2013; 27: 319–23
68.Shimauchi T, Hirakawa S, Suzuki T, Yasuma A, Majima Y, Tatsuno K et al. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. Journal of Dermatology. 2013; 40: 805–12
69.Fink AM, Cauza E, Hassfeld W, Dunky A, Bayer PM, Jurecka W et al. Vascular endothelial growth factor in patients with psoriatic arthritis. Clin Exp. Rheumatol. 2007; 25: 305-8
